Clinical and Experimental Hepatology

Abstract

1/2020 vol. 6
Original paper

Mac-2 binding protein in non-alcoholic fatty liver disease: Is it a reliable diagnostic biomarker? A pilot study

Rokaya Abd El-Aziz 1
,
Alshaimaa Rezk L R Alnaggar 1
,
Mona Ibrahim Mohamed Nabih 1
,
Shaimaa Mohammed Ali 1
,
Hany Khattab 2
,
Sahar Abd EL-Atty 3
  1. Internal Medicine Department, Kasr Alainy Hospital, Faculty of Medicine, Cairo University, Egypt
  2. Pathology Department, Kasr Alainy Hospital, Faculty of Medicine, Cairo University, Egypt
  3. Clinical and Chemical Pathology Department, Kasr Alainy Hospital, Faculty of Medicine, Cairo University, Egypt
Clin Exp HEPATOL 2020; 6, 1: 28–34
DOI: https://doi.org/10.5114/ceh.2020.93053
Online publish date: 2020/02/17
View full text
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease

Aim of the study

This study aimed to assess the level of serum Mac-2 binding protein (Mac-2BP) as a non-invasive biomarker for the diagnosis of non-alcoholic fatty liver disease (NAFLD).

Material and methods

Forty patients with NAFLD and 15 healthy sex- and age-matched subjects were included in this pilot study. Serum Mac-2BP level was measured using ELISA. Liver biopsy was taken from 20 patients.

Results

There was no statistically significant difference between patients and controls regarding the level of Mac-2BP (p = 0.209). Mac-2BP had a statistically significant correlation with the grade of lobular inflammation (r = 0.464, p = 0.039). The Mac-2BP cut-off value used for NASH prediction was 9.55 µg/ml, with sensitivity and specificity of 100% and 91.7%, respectively.

Conclusions

This study showed that Mac-2BP is not elevated in NAFLD patients compared to controls. It also demonstrated that the reliability of Mac-2BP as a biomarker for NAFLD diagnosis is still controversial and needs more investigation.

Keywords

Mac-2BP, biomarker, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis

Share
Coverage in
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications